Carvolix is a French medtech company in the commercial and clinical stages, founded by Truffle Capital, with the ambition of becoming a global leader in the treatment of structural heart disease and ischemic strokes—two of the world's leading causes of death and disability.
Carvolix develops new AI- and image-guided micro-robots that enable interventional cardiologists to perform complex procedures more effectively, as well as next-generation biomimetic heart valves.
